Alaa Abbas Fadhel

Alaa Abbas Fadhel

Auto-generated profile, based on publicly available information

Alaa Abbas Fadhel

Al-Mussaib technical college/ Al-FuratAl-Awsat Technical University, Iraq

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Talanta
Verified
Journal Article
Closed access
AFAlaa A. Fadhel
Alaa A. Fadhel
MJMadeleine Johnson
Madeleine Johnson
KTKhang Trieu
Khang Trieu
EKEda Koculi
Eda Koculi
ACAndrés Campiglia
Andrés Campiglia

1 November 2016 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AFAlaa A Fadhel
Alaa A Fadhel
XYXiling Yue
Xiling Yue
EZEbrahim H Ghazvini Zadeh
Ebrahim H Ghazvini Zadeh
MBMykhailo V Bondar
Mykhailo V Bondar
KBKevin D. Belfield
Kevin D. Belfield
Photodynamic therapy (PDT) processes involving the production of singlet oxygen face the issue of oxygen concentration dependency. Despite high oxygen delivery, a variety of properties related to metabolism and vascular morphology in cancer cells result in hypoxic environments, resulting in limited effectiveness of such therapies. An alternative oxygen-independent agent whose cell cytotoxicity can be remotely controlled by light may allow access to treatment of hypoxic tumors. Toward that end, we developed and tested both polyethylene glycol (PEG)-functionalized and hydrophilic silica nanoparticle (SiNP)-enriched photoacid generator (PAG) as a nontraditional PDT agent to effectively induce necrotic cell death in HCT-116 cells. Already known for applications in lithography and cationic polymerization, our developed oxygen-independent PDT, whether free or highly monodispersed on SiNPs, generates acid when a one-photon (1P) or two-photon (2P) excitation source is used, thus potentially permitting deep tissue treatment. Our study shows that when conjugated to SiNPs with protruding amine functionalities (SiNP–PAG9), such atypical PDT agents can be effectively delivered into HCT-116 cells and compartmentalize exclusively in lysosomes and endosomes. Loss of cell adhesion and cell swelling are detected when an excitation source is applied, suggesting that SiNP–PAG9, when excited via near-infrared 2P absorption (a subject of future investigation), can be used as a delivery system to selectively induce cell death in oxygen-deprived optically thick tissue.

15 September 2022 in Bionatura
Verified
Journal Article
Open access
AAAbeer Anwer Ahmed
Abeer Anwer Ahmed
KKKhaleed J. Khaleel
Khaleed J. Khaleel
AFAlaa Abbas Fadhel
Alaa Abbas Fadhel
BABahaa Abdullah Laftaah Al-Rubaii
Bahaa Abdullah Laftaah Al-Rubaii
Chronic myeloid leukemia (CML), is one of the myeloproliferative disorders with a characteristic cytogenetic abnormality resulting in the BCR-ABL fusion gene. Imatinib Mesylate is an effective agent for treating patients in all stages of CML. According to the annual Iraqi cancer registry 2019, the total number of chronic myeloproliferative disorders was 338. The percentage and incidence rates were 0.94% and 0.86%, respectively, with a higher incidence rate in males than females (1.12 in males and 0.60 in females). In this registry, no details about CML, so this study aimed to estimate the number of CML patients who attended the national center of hematology from 2005 until 2020 and investigate their epidemiological and clinic-pathological data. All data were obtained from the National Center of Hematology /Baghdad. Data regarding annual admission, number of deaths, and information about age, regions, and sex, were collected from patient cards. Interview and history taking from the patient and reviewing their clinical features at diagnosis were performed, and then statistical analysis was achieved. Two hundred sixteen patients were registered as CML; among them, 163 are still alive, while 53 died. The mean age at diagnosis was 40.39 ±14.30, with a male-to-female ratio of 1:1.16. The pediatrics age group comprises 3.7% of total cases and 1.8 % and 9.4% in the alive and dead groups, respectively. The percentages of death were higher in the pediatric age group, 62,5%( 5 /8), followed by the patient group who were ≥60 years, 42.1%(8/19), while it was the least in adults < 60 years, 21.1% (40/189). In conclusion, the studied patients with CML were younger than the globally reported ages at diagnosis, with predominant female patients. Females had better survival, while children and the elderly were the worse. Most patients were symptomatic at diagnosis; however, a good outcome is achieved when treated with IM. Keywords: CML, Imatinib, leukemia,

1 April 2019 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
MJMadeleine Johnson
Madeleine Johnson
AFAlaa Fadhel
Alaa Fadhel
KTKhang Trieu
Khang Trieu
JDJonathan Daniel
Jonathan Daniel
MBMelanie Beazley
Melanie Beazley
ACAndrés Campiglia
Andrés Campiglia

1 September 2019 in Journal of Physics: Conference Series
Verified
Conference Paper
Open access
PDF file
AAAdil A Awad
Adil A Awad
MHMohammed Mujbel Hasson
Mohammed Mujbel Hasson
AFAlaa Abbas Fadhel
Alaa Abbas Fadhel
BABassam Faron Alfarhani
Bassam Faron Alfarhani
New schiff base bis (salicylidene) tetramethylbenzidine (bstmb) was prepared via the condensation of salicylaldehyde with 3, 3−, 5,5−-tetramethylbenzidine in an ethanol solution. Four complexes were prepared by reaction of schiff base with metal acetat where m(ii),[co, ni, cu, and zn]. The schiff base ligand and their complexes were characterized by using infrared, 1h nmr spectroscopy, uv-visible spectra, solubility, melting point, (c.h.n) analysis, and molar conductance. The potentiometer analysis of the metal complexes revealed 1:1 (schiff base: metal particle) stoichiometry.

15 November 2021 in Bionatura
Verified
Journal Article
Open access
AAAbeer Anwer Ahmed
Abeer Anwer Ahmed
KKKhaleed J Khaleel
Khaleed J Khaleel
AFAlaa Abbas Fadhel
Alaa Abbas Fadhel
Imatinib Mesylate is an oral chemotherapy drug that has been used to treat Chronic Myelogenous Leukemia (CML). It works as an inhibitor of oncogene tyrosine kinase BCR-ABLI as a target therapeutic agent. Despite the drug is well tolerated in most patients, impaired testosterone production and Gynecomastia after therapy might happen. The current study aims to evaluate the impact of Imatinib Mesylate on sex hormones of CML male patients in Baghdad province. Blood specimens were collected from (42) CML patients aged 23 to 68 years who used Imatinib drug for more than two years, and (45) normal persons aged 25 to 65 years as a control group. Exclusion criteria were performed for both control and CML patient's groups, including people with diabetes, hypertensive, and males complaining of infertility after taking medical history for every participant. The blood level of hemoglobin (Hb), white blood cells (WBC), platelet count, testosterone, LH, and FSH were evaluated and investigated. The obtained results showed a significantly lower level of testosterone (2.73+- 0.97) ng/mL than the control group (4.72 ±1.02) ng/mL with a p-value of 0.000. While LH (4.53±2.1) mIU/mL and FSH (5.12 ± 2.83) mIU/mL were significantly higher than the control group (3.77± 0.8) mIU/mL and (3.85±0.807) mIU/mL with p-value of 0.026 and 0.005 respectively. Moreover, the outcomes revealed a moderate positive correlation (r = +0.348) between LH hormone levels with a duration increasing time of using Imatinib, while platelet showed a moderate negative correlation (r = -0.321) with time-consuming using that drug. In conclusion, Imatinib might harm testis functions and some hematological parameters that could increase using this drug.